This article introduces the requirements for a biosimilar license in Brazil and addresses questions about their quality, safety, and efficacy.
Sílvia Helena Cestari de Oliveira
Advertisement
Sílvia Helena Cestari de Oliveira is researcher in the biotechnology division at Cristália Produtos Químicos Farmacêuticos, Itapira, Brazil.
Articles by Sílvia Helena Cestari de Oliveira
Advertisement
Latest Updated Articles
Brazilian Regulation of Biosimilar Products: What Is Important to KnowPublished: September 2nd 2022 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
